These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 8865549)
41. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects. Hay CR; Lozier JN; Lee CA; Lafan M; Tradati H; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A Semin Hematol; 1994 Apr; 31(2 Suppl 4):20-5. PubMed ID: 7939768 [No Abstract] [Full Text] [Related]
42. [Production of factor VIII preparations and their use in the substitution therapy of hemophilia A]. Gaerisch F; Stein P Z Gesamte Inn Med; 1982 Oct; 37(19):641-4. PubMed ID: 6817530 [TBL] [Abstract][Full Text] [Related]
43. Prevalence of the intron 22 inversion of the factor VIII gene and inhibitor development in Polish patients with severe hemophilia A. Sawecka J; Skulimowska J; Windyga J; Lopaciuk S; Kościelak J Arch Immunol Ther Exp (Warsz); 2005; 53(4):352-6. PubMed ID: 16088320 [TBL] [Abstract][Full Text] [Related]
44. Analysis of factor VIII inhibitors using hybrid human/porcine factor VIII. Lollar P Thromb Haemost; 1997 Jul; 78(1):647-51. PubMed ID: 9198232 [TBL] [Abstract][Full Text] [Related]
45. Suggestions for the management of factor VIII inhibitors. Rubinger M; Rivard GE; Teitel J; Walker H; Haemophilia; 2000 Jul; 6 Suppl 1():52-9. PubMed ID: 10982269 [No Abstract] [Full Text] [Related]
46. Recombinant factor VIII: are we really getting more for less? Gorlin JB; Ewenstein BM J Pediatr; 1997 Apr; 130(4):507-9. PubMed ID: 9108841 [No Abstract] [Full Text] [Related]
47. A rebuttal: Issues with the assay of factor VIII activity in plasma and factor VII concentrates. Rosén S Thromb Haemost; 2001 Oct; 86(4):1132-3. PubMed ID: 11686346 [No Abstract] [Full Text] [Related]
48. The current status of recombinant human factor VIII. Aronson DL Semin Hematol; 1991 Apr; 28(2 Suppl 1):55-6. PubMed ID: 1908131 [No Abstract] [Full Text] [Related]
49. Hemophilia. Strategies for the treatment of inhibitor patients. Ingerslev J Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863 [TBL] [Abstract][Full Text] [Related]
50. Relationship between factor VIII replacement therapy and joint damage in severe haemophilia. Lowe GD Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S3-5. PubMed ID: 9351528 [TBL] [Abstract][Full Text] [Related]
51. Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine. Ambriz Fernandez R; Quintana Gonzalez S; Martinez Murillo C; Dominguez Garcia V; Rodriguez Moyado H; Collazo Jaloma J Arch Med Res; 1996; 27(1):15-8. PubMed ID: 8867361 [TBL] [Abstract][Full Text] [Related]
52. Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia. Lange D; Lazerson J Wis Med J; 1982 Feb; 81(2):28-31. PubMed ID: 6803446 [No Abstract] [Full Text] [Related]
53. [On the study of inhibitor of factor VIII in patients with hemophilia A]. Papaian-Pokrysheva LP Probl Gematol Pereliv Krovi; 1966 Nov; 11(11):46-8. PubMed ID: 6001925 [No Abstract] [Full Text] [Related]
54. Treatment of single factor deficiencies: a case study approach. Marques MB Clin Lab Sci; 2003; 16(2):120-2. PubMed ID: 12757193 [No Abstract] [Full Text] [Related]
55. The use of porcine factor VIII in Japan. Yoshioka A; Shima M; Morichika S; Terada S; Fukui H Semin Hematol; 1994 Apr; 31(2 Suppl 4):26-8. PubMed ID: 7939769 [No Abstract] [Full Text] [Related]
56. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil. Rieger A; Roisenberg I Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489 [No Abstract] [Full Text] [Related]
57. A combination of prednisone, high-dose intravenous immunoglobulin and desmopressin in the treatment of acquired hemophilia A with high-titer inhibitor. Gandini G; Franchini M; Manzato F; Lippi G; Aprili G Haematologica; 1999 Nov; 84(11):1054. PubMed ID: 10553173 [No Abstract] [Full Text] [Related]
58. [Successful treatment of hemothorax with recombinant factor VIIa in a hemophilic child with inhibitor]. Hulíková M; Galajda P; Kubisz P Vnitr Lek; 1998 Sep; 44(9):547-50. PubMed ID: 10358467 [TBL] [Abstract][Full Text] [Related]
59. [Lymphocyte T population in hemophilia A and its relation with factor VIII therapy and the presence of HBsAg or anti-F.VIII:C inhibitors]. Aznar JA; Carbonell F; Jorquera JI; Carmona E; Sánchez-Cuenca JM; Trénor A; de Andrés-Medina R; González-Molina A Sangre (Barc); 1985; 30(5):821-30. PubMed ID: 3937253 [No Abstract] [Full Text] [Related]
60. [in vivo reappearance of injected cryoprecopitate (factor VIII concentrates) in patients with hemophilia A]. Kuble M; Wegner H; Cron D Z Gesamte Inn Med; 1973 Oct; 28(20):608-14. PubMed ID: 4767194 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]